Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Feb 13 | 2023Insulet Acquires Bigfoot’s Insulin Pump IP; Dexcom G7 Receives Medicare Reimbursement; Novo Initiates New Sema Pediatric Obesity Trial; Sanofi Completes $35M Investment in Provention; Sanofi Announces Change in R&D LeadershipPurchase Blast
$599
Posted in: Other, SGLT2i Feb 10 | 2023Novo Nordisk and Heartseed Dose First Patient in Ph1/2 LAPiS Trial of HS-001; Finerenone Receives EU Approval for FIGARO-DKD Label ExtensionPurchase Blast
$599
Posted in: Basal Insulin, Other, SGLT2i Feb 09 | 2023AZ Q4 ’22 Earnings; Oramed to Consider M&A OpportunitiesPurchase Blast
$599
Posted in: Glucose Monitoring, Other Feb 08 | 2023Vertex Q4 ’22 Earnings; Dario Partners with DexcomPurchase Blast
$599
Posted in: Glucose Monitoring, Other, SGLT2i Feb 07 | 2023Dexcom G7 Super Bowl DTC; Medtronic Initiates 780G+DS5 GCM Trial; Forxiga Receives EU Approval for Chronic HF; Merck Initiates Vericiguat Pediatric HF TrialPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Feb 03 | 2023Sanofi and Regeneron Q4 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Other, SGLT2i Feb 02 | 2023Lilly, Merck, and Roche Q4 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other Feb 01 | 2023Amgen, Novartis, and Lannett Q4 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, GLP-1RA + Basal Feb 01 | 2023Novo Nordisk Q4 ’22 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, SGLT2i Jan 31 | 2023Pfizer Q4 ’22 Earnings; Lilly Initiates Open-Label SURPASS-SWITCH-2 Study; Fractyl Health Announces Positive Week 24 REVITA-T2Di Data; Sciwind Initiates Dosing for Ph3 Ecnoglutide Trials in China; Lifescan Announces Publication of Connected BGM RWEPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, SGLT2i Jan 27 | 2023Viatris’s Generic Dapagliflozin and Lilly’s Trulicity Pediatric Extension Receive Positive CHMP opinions; Medtronic’s Wearable Partner Files for Bankruptcy; Nemaura Looks to Raise Additional CapitalPurchase Blast
$599
Posted in: Glucose Monitoring, Other Jan 26 | 2023Diabetes Research Institute Appoints Matthias von Herrath as Scientific Director; Nemaura Receives First proBEAT Purchase Order from HealthFleetPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 25 | 2023Abbott Q4 ’22 Earnings; Tidepool Loop Receives FDA Clearance; Lilly to Expand Incretin Manufacturing Capacity; Novo Receives Marketing Practices Complaint; AGC Biologics to Manufacture Tzield; Nemaura Reports Positive Miboko Data; J&J Q4 ’22 Earnings; and Embecta Opens New HeadquartersPurchase Blast
$599
Posted in: Insulin Delivery, Other, SGLT2i Jan 23 | 2023Another Branded SGLT2i Approved by FDA; Tandem Completes AMF Medical Acquisition; January CHMP AgendaPurchase Blast
$599
Posted in: SGLT2i Jan 20 | 2023Jardiance CKD sNDA Accepted by FDA Without Priority ReviewPurchase Blast
$599
Posted in: Other Jan 19 | 2023FDA Accepts OCA NASH NDA; Palatin Initiates Ph2b DKD TrialPurchase Blast
$599
Posted in: DPP-IVi, Other Jan 18 | 2023Diamyd Initiates Ph2 Trial in At-risk Individuals; Teladoc Cuts 300 Jobs; Merck to Resolve Sitagliptin Contamination IssuePurchase Blast